Chemotherapy-induced Nausea and Vomiting Drugs Market

Chemotherapy induced nausea and vomiting (CINV) drugs refer to medication or treatment that is offered to cancer patients who experience nausea and vomiting due to chemotherapy.

Chemotherapy-induced Nausea and Vomiting Drugs Market contains market size and forecasts of Chemotherapy-induced Nausea and Vomiting Drugs in global, including the following market information:

Global Chemotherapy-induced Nausea and Vomiting Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Chemotherapy-induced Nausea and Vomiting Drugs Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Chemotherapy-induced Nausea and Vomiting Drugs companies in 2021 (%)

The global Chemotherapy-induced Nausea and Vomiting Drugs market was valued at 1738.3 million in 2021 and is projected to reach US$ 2320.1 million by 2028, at a CAGR of 4.2% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

5-HT3 Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Chemotherapy-induced Nausea and Vomiting Drugs include Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Heron Therapeutics, Roche and Mylan and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

Wesurveyed the Chemotherapy-induced Nausea and Vomiting Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chemotherapy-induced Nausea and Vomiting Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Chemotherapy-induced Nausea and Vomiting Drugs Market Segment Percentages, by Type, 2021 (%)

5-HT3 Inhibitors

NK1 Inhibitors

Other

Global Chemotherapy-induced Nausea and Vomiting Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Chemotherapy-induced Nausea and Vomiting Drugs Market Segment Percentages, by Application, 2021 (%)

Highly Emetogenic Chemotherapy

Moderately Emetogenic Chemotherapy

Low Emetogenic Chemotherapy

Other

Global Chemotherapy-induced Nausea and Vomiting Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Chemotherapy-induced Nausea and Vomiting Drugs Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Chemotherapy-induced Nausea and Vomiting Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Chemotherapy-induced Nausea and Vomiting Drugs revenues share in global market, 2021 (%)

Key companies Chemotherapy-induced Nausea and Vomiting Drugs sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Chemotherapy-induced Nausea and Vomiting Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Merck

Eisai

Mundipharma

Qilu Pharma

Teva

Novartis

Heron Therapeutics

Roche

Mylan

Tesaro